drugset / Trial / NCT00648102

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer

NCT00648102

Phase 1 Completed 36 enrolled Celldex Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additional treatments, in combination, thought to enhance the immune response effect. This study specifically administers the vaccine systemically to explore whether dendritic cell targeted vaccines can generate more robust effects via intravenous injection. (CDX 1307-02)

Timeline

Start
2006-01
Primary completion
2009-05
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CDX-1307 Vaccine Intravenous